Notis McConarty Edward Sells 265 Shares of Amgen Inc. (AMGN)
Notis McConarty Edward lessened its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 14,292 shares of the medical research company’s stock after selling 265 shares during the quarter. Amgen makes up approximately 1.5% of Notis McConarty Edward’s holdings, making the stock its 24th biggest holding. Notis McConarty Edward’s holdings in Amgen were worth $2,344,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also modified their holdings of the company. TrimTabs Asset Management LLC boosted its stake in shares of Amgen by 88.9% in the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after purchasing an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC boosted its stake in shares of Amgen by 19.0% in the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after purchasing an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its stake in shares of Amgen by 0.6% in the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after purchasing an additional 4 shares during the last quarter. Nelson Roberts Investment Advisors LLC bought a new position in shares of Amgen in the 1st quarter valued at about $121,000. Finally, Signature Estate & Investment Advisors LLC boosted its stake in shares of Amgen by 13.6% in the 1st quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after purchasing an additional 95 shares during the last quarter. 78.14% of the stock is currently owned by institutional investors.
Several research analysts have recently issued reports on the stock. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $203.00 target price on shares of Amgen in a research note on Thursday, September 7th. Cann reaffirmed a “buy” rating on shares of Amgen in a research note on Monday, August 28th. Mizuho reaffirmed a “buy” rating and issued a $183.00 target price (down previously from $195.00) on shares of Amgen in a research note on Monday, August 21st. BidaskClub lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Argus raised their target price on shares of Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $186.04.
Amgen Inc. (NASDAQ AMGN) traded up 0.99% during mid-day trading on Tuesday, hitting $188.33. 1,421,434 shares of the stock were exchanged. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $188.85. The company has a market capitalization of $137.42 billion, a PE ratio of 17.15 and a beta of 1.35. The stock has a 50 day moving average price of $173.58 and a 200 day moving average price of $168.69.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same period last year, the business earned $2.84 EPS. Amgen’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, equities analysts anticipate that Amgen Inc. will post $12.57 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were issued a $1.15 dividend. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.47%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio is currently 41.93%.
TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/12/notis-mcconarty-edward-sells-265-shares-of-amgen-inc-amgn.html.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.